NCT00111683View on ClinicalTrials.gov

MK0457 in Patients With Leukemia (0457-003)

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Chronic Myelogenous Leukemia in Blast CrisisLymphocytic Leukemia, B Cell, AcuteMyelodysplastic SyndromesMyelogenous Leukemia, Chronic
Interventions
DRUG

MK0457

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00111683 - MK0457 in Patients With Leukemia (0457-003) | Biotech Hunter | Biotech Hunter